GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akers Biosciences Inc (NAS:AKER) » Definitions » Cash Flow from Investing

Akers Biosciences (Akers Biosciences) Cash Flow from Investing : $-8.76 Mil (TTM As of Dec. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Akers Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2020, Akers Biosciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $9.77 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $1.20 Mil for other investing activities. In all, Akers Biosciences spent $10.97 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2020.


Akers Biosciences Cash Flow from Investing Historical Data

The historical data trend for Akers Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akers Biosciences Cash Flow from Investing Chart

Akers Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 -5.02 -0.36 -3.94 -8.76

Akers Biosciences Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.31 2.26 -0.03 -0.02 -10.97

Akers Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Akers Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2020 is calculated as:

Akers Biosciences's Cash Flow from Investing for the quarter that ended in Dec. 2020 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akers Biosciences  (NAS:AKER) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Akers Biosciences's purchase of property, plant, equipment for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Akers Biosciences's sale of property, plant, equipment for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Akers Biosciences's purchase of business for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Akers Biosciences's sale of business for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Akers Biosciences's purchase of investment for the three months ended in Dec. 2020 was $-9.77 Mil. It means Akers Biosciences spent {stock_data.stock.currency_symbol}}9.77 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Akers Biosciences's sale of investment for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Akers Biosciences's net Intangibles purchase and sale for the three months ended in Dec. 2020 was $0.00 Mil. It means Akers Biosciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Akers Biosciences's cash from discontinued investing activities for the three months ended in Dec. 2020 was 0.00 Mil. It means Akers Biosciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Akers Biosciences's cash from other investing activities for the three months ended in Dec. 2020 was $-1.20 Mil. It means Akers Biosciences paid $1.20 Mil for other investing activities.


Akers Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Akers Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Akers Biosciences (Akers Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
Executives
Billy Joe White director 191 OTTO ST., PORT TOWNSEND WA 98368
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Christopher C Schreiber director, officer: Exec. Chairman and President AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
John J Gormally director, officer: Chief Executive Officer 80 WALSH DRIVE, MAHWAH NJ 07430
Gary M Rauch officer: VP - Finance, Treasurer 842 ST REGIS COURT, WEST DEPTFORD NJ 08051
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Brandon Thomas Knox director 771 EAGLE ROAD, VILLANOVA PA 19085
Akers Raymond Francis Jr director, officer: Executive Chairman, Secretary 171 E. ESSEX AVE, SEWELL NJ 08080
Thomas J Knox director 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103
Robert E Andrews director 215 4TH AVENUE, HADDON HEIGHTS NJ 08035